These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17353448)

  • 21. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.
    Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB
    Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.
    Johansson I; Andersson R; Friman V; Selimovic N; Hanzen L; Nasic S; Nyström U; Sigurdardottir V
    BMC Infect Dis; 2015 Dec; 15():582. PubMed ID: 26703239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients.
    Snydman DR; Kistler KD; Ulsh P; Morris J
    Transplantation; 2010 Dec; 90(12):1432-8. PubMed ID: 21076378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
    Travi G; Pergam SA; Xie H; Boeckh MJ
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):758-60. PubMed ID: 19450762
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
    Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus infection after kidney transplantation and long-term graft loss.
    López-Oliva MO; Flores J; Madero R; Escuin F; Santana MJ; Bellón T; Selgas R; Jiménez C
    Nefrologia; 2017; 37(5):515-525. PubMed ID: 28946964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation.
    Hellinger WC; Bonatti H; Machicao VI; Yao JD; Brumble LM; Alvarez S; Weigand SD; Dickson RC; Harnois DM; Spivey JR; Stapelfeldt WH; Hughes CB; Nguyen JH; Steers JL
    Mayo Clin Proc; 2006 Aug; 81(8):1029-33. PubMed ID: 16901025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R
    Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.
    Klimczak-Tomaniak D; Roest S; Brugts JJ; Caliskan K; Kardys I; Zijlstra F; Constantinescu AA; Voermans JJC; van Kampen JJA; Manintveld OC
    Transplantation; 2020 Jul; 104(7):1508-1518. PubMed ID: 31644496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
    Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines.
    Dmitrienko S; Balshaw R; Machnicki G; Shapiro RJ; Keown PA
    Transplantation; 2009 Feb; 87(4):570-7. PubMed ID: 19307796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients.
    Nafar M; Roshan A; Pour-Reza-Gholi F; Samadian F; Ahmadpoor P; Samavat S; Abbasi MA
    Iran J Kidney Dis; 2014 May; 8(3):231-5. PubMed ID: 24878947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus-related complications in human hand transplantation.
    Schneeberger S; Lucchina S; Lanzetta M; Brandacher G; Bösmüller C; Steurer W; Baldanti F; Dezza C; Margreiter R; Bonatti H
    Transplantation; 2005 Aug; 80(4):441-7. PubMed ID: 16123716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.